Vanda Pharmaceuticals | VNDA - Cost Of Sales


Vanda Pharmaceuticals reported $198.77M in Cost of Sales for its fiscal quarter ending in December of 2024.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Akebia Therapeutics USD 8.13M 2.41M Mar/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Anika Therapeutics USD 11.49M 35.48M Mar/2025
AstraZeneca USD 3.27B 471M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Esperion Therapeutics USD 51.63M 22.2M Sep/2024
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Heron Therapeutics USD 9.46M 1.61M Sep/2024
Insmed USD 46.16M 15.25M Dec/2025
J&J USD 7.97B 689M Dec/2025
Lexicon Pharmaceuticals USD 17.81M 3.41M Jun/2024
Ligand Pharmaceuticals USD 11.9M 733K Sep/2025
Merck USD 3.32B 531M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Moderna USD 452M 245M Dec/2025
Novartis USD 3.54B 216M Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 4.29B 421M Dec/2025
Takeda JPY 401.15B 184.07B Dec/2025
Teva Pharmaceutical Industries USD 2.06B 120M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Veracyte USD 39.28M 1.93M Dec/2025